Authors : Ashwini Bhalerao Gandhi, Ameya Purandare, Kavitha Athota, Priya Ganesh Kumar, Sudha Tandon, Shobhit Seth, Poonam Shah
DOI : 10.18231/j.ijogr.2022.063
Volume : 9
Issue : 3
Year : 2022
Page No : 328-334
Vulvovaginal candidiasis (VVC) is a commonly encountered clinical condition. At least three-fourth women experience one episode of VVC in their lifetime. In India, the prevalence of VVC is 10 to 35%. Laboratory methods often supplement clinical diagnosis. VVC should be confirmed with culture and other investigative techniques, especially in complicated and recurrent cases. Topical and intravaginal azoles remain the mainstay of therapy. In women who have predisposing risk factors or develop recurrent VVC, oral antifungal agents are used. Topical steroids may be used in women having vulvar symptoms along with pruritus. Pregnancy is a significant risk factor. Intravaginal azoles remain the standard of treatment and can be offered from the second trimester onwards. The emergence of non-albicans species has caused difficulties in the management of VVCs. Thus, all women with vaginal discharge should be correctly diagnosed to tailor the therapy.
Keywords: Candida albicans, Vaginitis, Antifungal drugs, Vulvovaginal infections